CTOs on the Move

Diagnostic Solutions Laboratory

www.diagnosticsolutionslab.com

 
We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alto Neuroscience

Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Our artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

Optimum Outcomes

Optimum Outcomes is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.

Benitec Ltd

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.

Quadrant Biosciences

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.